Epidermal growth factor receptor (EGFR) inhibitors have been successfully used as co-drugs to improve the prognosis of non-small cell lung cancer (NSCLC) expressing EGFRs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.